Lower BDNF Levels Linked to Parkinson's Disease

Strategic Insights -

Researchers from the Fourth People's Hospital of Shenyang in the People's Republic of China have conducted a comprehensive study on the association between brain-derived neurotrophic factor (BDNF) levels and Parkinson's disease. The study, involving 48 articles and a total of 2,589 patients with PD and 2,422 healthy controls, found that patients with Parkinson's disease had significantly lower peripheral blood BDNF levels compared to healthy controls. This research may have significant implications for the potential use of BDNF as a biomarker for non-motor symptoms of Parkinson's disease.

Key Takeaways:

  • The study aimed to examine BDNF levels in patients with Parkinson's disease and explore their correlation with non-motor symptoms, specifically cognitive impairment.
  • A total of 38 studies were analyzed, covering 2,589 patients with PD and 2,422 healthy controls, revealing significantly lower peripheral blood BDNF levels in PD patients.
  • The study found that PD patients had a standardized mean difference (SMD) of -1.037 (95% CI [-1.412, -0.662]) compared to healthy controls, indicating a significant decrease in BDNF levels.
  • The research may have potential implications for the use of BDNF as a biomarker for non-motor symptoms of Parkinson's disease, particularly cognitive impairment.
  • The study suggests that further research is needed to explore the relationship between BDNF levels and Parkinson's disease, including the potential use of BDNF as a biomarker for non-motor symptoms.
  • A comprehensive systematic review and meta-analysis was conducted, encompassing 48 articles.
  • The study used the Newcastle-Ottawa Scale (NOS) to assess the quality of the included studies.
  • Standardized mean differences (SMDs) with 95% confidence intervals (CIs) were calculated using Stata version 14.0, applying either a fixed-effect or a random-effects model based on heterogeneity.
  • Publication bias was assessed using funnel plots and Egger's test.

Statistics:

  • A total of 2,589 patients with Parkinson's disease were included in the analysis.
  • 2,422 healthy controls were included in the analysis.
  • The study found a standardized mean difference (SMD) of -1.037 (95% CI [-1.412, -0.662]) between PD patients and healthy controls.
  • The study included 48 articles and conducted a comprehensive systematic review and meta-analysis.

Sources:

  • Association of brain-derived neurotrophic factor in blood and cerebrospinal fluid with Parkinson's disease and non-motor symptoms of Parkinson's disease: a systematic review and meta-analysis of 6655 participants. Frontiers in Aging Neuroscience, 2025;17:1620172.
  • Frontiers in Aging Neuroscience, Avenue Du Tribunal Federal 34, Lausanne, Ch-1015, Switzerland.
  • NewsRx. Reports from Fourth People's Hospital Advance Knowledge in Parkinson's Disease (Association of brain-derived neurotrophic factor in blood and cerebrospinal fluid with Parkinson's disease and non-motor symptoms of Parkinson's disease: a ...). Health & Medicine Week. October 24, 2025; p 4606.